COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 15, 2021

Pingali, Cassandra; Meghani, Mehreen; Razzaghi, Hilda; Lamias, Mark J.; Weintraub, Eric; Kenigsberg, Tat'Yana A.; Klein, Nicola P.; Lewis, Ned; Fireman, Bruce; Zerbo, Ousseny; Bartlett, Joan; Goddard, Kristin; Donahue, James G.; Hanson, Kayla E.; Naleway, Allison L.; Kharbanda, Elyse O.; Yih, W. Katherine; Nelson, Jennifer C.; Lewin, Bruno; Williams, Joshua T.B.; Glanz, Jason M.; Singleton, James A.; Patel, Suchita A.

doi:10.15585/mmwr.mm7028a1

Cited by 36 publications

(28 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Differences in COVID19 vaccination according to ethnicity has also been observed in other countries such as the UK 27 and the USA. 28 However, it is important to note that unlike most ethnic minorities in other countries, Arabs in Israel achieve higher vaccine coverage for routine vaccination than the Jewish majority. 29 …”

Section: Discussionmentioning

confidence: 99%

Inequalities in initiation of COVID19 vaccination by age and population group in Israel- December 2020-July 2021

Gorelik

Anis

Edelstein

2022

The Lancet Regional Health - Europe

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Inequalities in initiation of COVID19 vaccination by age and population group in Israel- December 2020-July 2021

Gorelik

Anis

Edelstein

2022

The Lancet Regional Health - Europe

View full text Add to dashboard Cite

“…Sites included race and ethnicity to identify disparities regarding vaccination rates. 12,13 In response to the pandemic, we created additional weekly files, including COVID-19 diagnoses and laboratory results. Surveillance included the 10 162 227 members of participating health plans aged 12 years or older.…”

Section: Setting and Study Populationmentioning

confidence: 99%

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Klein

Lewis

Goddard

et al. 2021

JAMA

Self Cite

510

502

View full text Add to dashboard Cite

IMPORTANCE Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.OBJECTIVES To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population. DESIGN, SETTING, AND PARTICIPANTSThis study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.EXPOSURES Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2.MAIN OUTCOMES AND MEASURES Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke, and thrombosis with thrombocytopenia syndrome. Incidence of events that occurred among vaccine recipients 1 to 21 days after either dose 1 or 2 of a messenger RNA (mRNA) vaccine was compared with that of vaccinated concurrent comparators who, on the same calendar day, had received their most recent dose 22 to 42 days earlier. Rate ratios (RRs) were estimated by Poisson regression, adjusted for age, sex, race and ethnicity, health plan, and calendar day. For a signal, a 1-sided P < .0048 was required to keep type I error below .05 during 2 years of weekly analyses. For 4 additional outcomes, including anaphylaxis, only descriptive analyses were conducted.RESULTS A total of 11 845 128 doses of mRNA vaccines (57% BNT162b2; 6 175 813 first doses and 5 669 315 second doses) were administered to 6.2 million individuals (mean age, 49 years; 54% female individuals). The incidence of events per 1 000 000 person-years during the risk vs comparison intervals for ischemic stroke was 1612 vs 1781 (RR, 0.97; 95% CI, 0.87-1.08); for appendicitis, 1179 vs 1345 (RR, 0.82; 95% CI, 0.73-0.93); and for acute myocardial infarction, 935 vs 1030 (RR, 1.02; 95% CI, 0.89-1.18). No vaccine-outcome association met the prespecified requirement for a signal. Incidence of confirmed anaphylaxis was 4.8 (95% CI, 3.2-6.9) per million doses of BNT162b2 and 5.1 (95% CI, 3.3-7.6) per million doses of mRNA-1273. CONCLUSIONS AND RELEVANCEIn interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.

show abstract

“…After the introduction of the vaccine, we have shown a significant difference in seropositivity rate by ethnicity as Jews and others were more likely than Arabs to be seropositive. Differences in COVID-19 vaccination according to ethnicity were also demonstrated in the UK [ 25 ] and the USA [ 18 , 26 ]. This finding may be explained by the low COVID-19 vaccination rates among the Arab population in Israel, as was previously reported [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

et al. 2022

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech vaccine, and on 20 December, an immunization campaign began among adults in Israel. We characterized seropositivity for IgG anti-spike antibodies against SARS-CoV-2 between January 2020 and July 2021, before and after the introduction of the vaccine in Israel among adults. We tested 9520 serum samples, collected between January 2020 and July 2021. Between January and August 2020, seropositivity rates were lower than 5.0%; this rate increased from September 2020 (6.3%) to April 2021 (84.9%) and reached 79.1% in July 2021. Between January and December 2020, low socio-economic rank was an independent, significant correlate for seropositivity. Between January and July 2021, the 40.00–64.99-year-old age group, Jews and others, and residents of the Northern district were significantly more likely to be seropositive. Our findings indicate a slow, non-significant increase in the seropositivity rate to SARS-CoV-2 between January and December 2020. Following the introduction of the Pfizer-BioNTech vaccine in Israel, a significant increase in seropositivity was observed from January until April 2021, with stable rates thereafter, up to July 2021.

show abstract

COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 15, 2021

Cited by 36 publications

References 3 publications

Inequalities in initiation of COVID19 vaccination by age and population group in Israel- December 2020-July 2021

Inequalities in initiation of COVID19 vaccination by age and population group in Israel- December 2020-July 2021

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

Contact Info

Product

Resources

About